Clinical Trial Update: Evaluation of Dupilumab in Chinese Adult Patients With Moderate to Severe Atopic Dermatitis [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating dupilumab in Chinese adults with moderate-to-severe atopic dermatitis has completed and results were posted in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• Dupilumab (dupilumab)

Snippet

Sponsor: Sanofi | Conditions: Atopic Dermatitis | Phase 3 | Status: COMPLETED | Results posted: 2021-04-05